London: Thursday, August 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To, purchased a total of 14,748 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on August 28 and 29, 2017 at an average price of US$24.40 per ADS. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust (the “DDT”) which has been established for the benefit of Mr To’s family members, of which Mr To is the settlor.
Following the above purchases, Mr To is interested in 133,237 ADSs (in DDT and Wencheng Trust of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.41% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Dynamic Drive Limited | |
| 2 | Reason for the notification | ||
| a) | Position/status | Person closely associated with Mr Simon To, Executive Director and Chairman. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust which has been established for the benefit of Mr To’s family members, of which Mr To is the settlor. | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hutchison China MediTech Limited | |
| b) | LEI | 2138006X34YDQ6OBYE79 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) |
Description of the financial instrument, type of instrument Identification code |
ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035 |
|
| b) | Nature of the transaction | Acquisition of a total of 14,748 ADSs in the name of Dynamic Drive Limited which holds the ADSs for a family trust (Dynamic Drive Trust) of which Mr To is the settlor on August 28 and 29, 2017 at an average price of US$24.40 per ADS. | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| US$24.47 | 5,554 | ||
| US$24.36 | 9,194 | ||
| d) |
Aggregated information – Aggregated volume – Price |
Aggregated volume: 14,748 ADSs Price information: US$24.40 |
|
| e) | Date of the transaction |
2017-08-28 – acquisition of 5,554 ADSs 2017-08-29 – acquisition of 9,194 ADSs |
|
| f) | Place of the transaction | Nasdaq Stock Market | |
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (“CK Hutchison”) (SEHK: 0001). For more information, please visit: www.chi-med.com.
Mark Lee, SVP Corporate Finance & Development
+852 2121 8200
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com
Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com
Matt Beck, The Trout Group
+1 (917) 415 1750 (Mobile)
mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedr.co.uk
Richard Gray / Andrew Potts
+44 (20) 7886 2500
2017年8月29日：和黃醫藥今日宣佈在中國啟動HMPL-689的I期臨床試驗。HMPL-689是一種新型高選擇性強效小分子抑製劑，靶向B 細胞受體信號通路中的關鍵蛋白磷酸肌醇-3激酶δ異構體（PI3Kδ）。
此次新啟動的I期臨床試驗是一項多中心開放標籤的兩階段研究，目標受試者為複發或難治性非霍奇金淋巴瘤患者，旨在評估HMPL- 689 單一療法的安全性、耐受性和藥代動力學特性（PK）並進行初步的療效評估。第一階段為劑量遞增期，主要目標為確定HMPL-689在此類患者群體中的最大耐受劑量（MTD）以及II期臨床試驗的推薦劑量（RP2D）。第二階段為劑量擴張期，將評估PR2D 劑量下HMPL-689在不同亞型患者群體中的安全性、耐受性和初步的療效。該研究詳情可登陸ClinicalTrials.gov，檢索NCT03128164查看。
PI3K信號傳導由4種不同的具有催化活性的異構體（p110α，β，γ，δ）介導。其中δ （delta）異構體是B 細胞受體信號通路中最為關鍵的異構體，也是已被證實的藥物靶點。這種異構體主要在造血細胞中表達，尤其在淋巴細胞中高度表達。
HMPL-689 是一種新型且有望成為“ 同類最佳“的小分子抑製劑，高選擇性強效靶向抑制PI3Kδ異構體，而對PI3K ɣ （gamma）及其他異構體無抑製作用，以最大程度地降低因免疫抑製而導致嚴重感染的風險。在臨床前PK研究中，HMPL-689展現出了口服吸收良好、中等程度組織分佈和低清除率等與預期一致的良好PK特性。該藥在全血水平尤其高效，也有望具有較低的藥物累積和藥物間相互作用的風險。
HMPL-689首次應用於人體的劑量遞增I期臨床試驗已於2016年在澳大利亞完成，受試者為健康成年志願者，試驗評估了單次口服給藥後HMPL-689的藥代動力學特性和安全性。試驗結果與預期一致，HMPL-689展現出了線性的PK特徵和良好的安全性。該研究詳情可登陸ClinicalTrials.gov，檢索NCT02631642查看。
London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) at an average price of US$24.99 per ADS on August 18 and 21, 2017.
Following the above purchases, Ms Shih is interested in 100,000 ADSs and 70,000 Ordinary Shares, representing approximately 0.20% of the current issued share capital of Chi-Med.
Please download the full announcement for the notification as provided in accordance with the requirements of the EU Market Abuse Regulation.
London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:-
(a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely associated (“PCA”) with Mr To, purchased a total of 4,900 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on August 15, 2017 at a price of US$24.50 per ADS. WCL is controlled by the trustee of Wencheng Trust (“WT”) which has been established for the benefit of Mr To’s family member, of which Mr To is the settlor; and
(b) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 5,336 ADSs at an average price of US$24.92 per ADS on August 16 and 17, 2017.
Following the above purchases, (i) Mr To is interested in 118,489 ADSs (in Dynamic Drive Trust (“DDT”) and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 96,000 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.
Please download the full announcement for the notifications as provided in accordance with the requirements of the EU Market Abuse Regulation.
Bridgehampton, NY, USA
London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:-
(a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“PCA”) with Mr To, purchased a total of 3,188 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on August 14, 2017 at a price of US$24.47 per ADS. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust (the “DDT”) which has been established for the benefit of Mr To’s family members, of which Mr To is the settlor; and
(b) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 5,001 ADSs at an average price of US$25.67 per ADS on August 10 and 11, 2017.
Following the above purchases, (i) Mr To is interested in 113,589 ADSs (in DDT and Wencheng Trust of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 90,664 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.
Please see the full announcement for the notifications as provided in accordance with the requirements of the EU Market Abuse Regulation.
London: Thursday, August 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) at an average price of US$26.18 per ADS on August 7 and 9, 2017.
Following the above purchases, Ms Shih is interested in 85,663 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.
Please see the full announcement for details as provided in accordance with the requirements of the EU Market Abuse Regulation.
London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:-
(a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“PCA”) with Mr To, purchased a total of 1,748 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med (“Ordinary Share”)) on August 2, 2017 at a price of US$22.97 per ADS. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust (the “DDT”) which has been established for the benefit of Mr To’s family members, of which Mr To is the settlor;
(b) Mr To through Wencheng Capital Limited (“WCL”), a PCA with Mr To, purchased a total of 1,826 ADSs between August 2 and August 3, 2017 at an average price of US$22.93 per ADS. WCL is controlled by the trustee of Wencheng Trust (“WT”) which has been established for the benefit of Mr To’s family member, of which Mr To is the settlor;
(c) Mr Paul Carter, Independent Non-executive Director, purchased a total of 724 Ordinary Shares at a price of GBP34.25 per share on August 2, 2017;
(d) Dr Dan Eldar, Non-executive Director, purchased a total of 1,900 Ordinary Shares at an average price of GBP34.93 per share on August 2, 2017;
(e) Dr Karen Ferrante, Independent Non-executive Director, purchased a total of 3,245 ADSs at an average price of US$22.94 per ADS on August 2, 2017; and
(f) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 7,712 ADSs and 10,000 Ordinary Shares at an average price of US$23.29 per ADS and GBP34.75 per share respectively between August 3 and August 4, 2017.
Following the above purchases, (i) Mr To is interested in 110,401 ADSs (in DDT and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; (ii) Mr Carter is interested in 3,524 Ordinary Shares, representing approximately 0.006% of the current issued share capital of Chi-Med; (iii) Dr Eldar is interested in 1,900 Ordinary Shares and 6,225 ADSs, representing approximately 0.008% of the current issued share capital of Chi-Med; (iv) Dr Ferrante is interested in 5,785 ADSs, representing approximately 0.005% of the current issued share capital of Chi-Med; and (v) Ms Shih is interested in 83,856 ADSs and 70,000 Ordinary Shares, representing approximately 0.18% of the current issued share capital of Chi-Med.
Please download the full announcement for the notifications provided in accordance with the requirements of the EU Market Abuse Regulation.